Transatlantic health technology investment fund launched by Meridan Health Ventures, claimed as the world's first of its kind.

Meridian Health Ventures, previously known as KHP Ventures, has announced the launch of a transatlantic healthtech fund aimed at providing growth opportunities for healthtech innovators in the UK and supporting UK innovation in the National Health Service (NHS).

The fund, which brings together leading health systems, venture investors, institutional investors, and academic centres of excellence, aims to accelerate innovation by strategically investing in and supporting early-stage health technology companies that operate across both the UK and US markets.

Boosting UK Innovation

The fund targets promising UK-based healthtech startups, offering them capital, mentorship, and access to the US market. This support helps UK innovators scale their solutions and commercialize cutting-edge technologies more effectively.

Creating Global Growth Opportunities

By focusing on transatlantic collaboration, the fund helps companies expand beyond domestic borders, tapping into larger and more diverse markets. This global outlook facilitates partnerships, customer acquisition, and regulatory navigation on both sides of the Atlantic.

Bridging UK and US Healthcare Systems

The fund fosters collaboration between the UK’s NHS-driven system and the predominantly private US healthcare market. It does this by enabling startups to tailor their solutions to both healthcare environments, encouraging knowledge transfer, and aligning regulatory and reimbursement strategies. This bridging helps accelerate adoption of technologies that can improve patient outcomes and operational efficiencies across healthcare systems.

A Strong Portfolio and Exciting Partnerships

The fund's portfolio includes health tech companies such as Doccla, deepc, Patchwork, Tympa Health, Apian, iFAST Diagnostics, PocDoc, Phare Health, 52 North, and MediShout. Cedars-Sinai Medical Center, one of the fund's partners, has been impressed by the quality and depth of the health tech founders in Meridian Health Ventures' portfolio and is excited to build on their collaboration as partners in the fund.

The NHS, which is facing challenges in delivering high-quality care against rising demand, increased patient acuity, and pressures on workforce and finance, is committed to harnessing accelerations in new digital and biomedical advances, such as the innovative start-ups that the fund invests in, to deliver better, faster, and fairer healthcare for all.

The partners in the fund will enable start-ups to generate real-world data and evidence for adoption within broader UK and US healthcare environments. Meridian Health Ventures' portfolio company, Apian, for example, has grown from its NHS origins and is now working with Zipline and Wing to deliver care to patients faster.

Apian's CEO and Co-Founder, Alex Trewby, highlights the importance of partnerships with organizations like Meridian Health Ventures and Trusts like Guy's and St Thomas' NHS Foundation Trust for their global mission.

The fund has invested in promising MedTech spin-outs from Cambridge, Oxford, Imperial, King's, and Southampton, counting 12 NHS clinical entrepreneurs amongst its company founders. The majority of the portfolio companies are expanding globally, including numerous companies working with US health system partners such as Cedars-Sinai.

Meridian Health Ventures' transatlantic fund is designed to stimulate UK healthtech innovation, open up international growth pathways, and create stronger connections between UK and US healthcare ecosystems, ultimately advancing global healthcare innovation and delivery. The fund will help healthtech superscalers to thrive domestically in the UK while fast-tracking their growth in the US.

Meridian Health Ventures, a transatlantic healthtech fund, aims to support UK innovation in the National Health Service (NHS) and provide growth opportunities for healthtech innovators in the UK and US markets.
The fund supports promising UK-based healthtech startups by offering them capital, mentorship, and access to the US market, helping them scale their solutions and commercialize cutting-edge technologies more effectively.
By focusing on transatlantic collaboration, the fund helps companies expand beyond domestic borders, facilitating partnerships, customer acquisition, and regulatory navigation on both sides of the Atlantic.
The fund fosters collaboration between the UK’s NHS-driven system and the predominantly private US healthcare market, enabling startups to tailor their solutions to both healthcare environments and aligning regulatory and reimbursement strategies.
The fund's portfolio includes health tech companies like Doccla, deepc, Patchwork, Tympa Health, Apian, iFAST Diagnostics, PocDoc, Phare Health, 52 North, and MediShout, with partnerships that include Cedars-Sinai Medical Center.
The NHS, facing challenges in delivering high-quality care, is committed to harnessing accelerations in digital and biomedical advances like the innovative start-ups funded by the fund to deliver better, faster, and fairer healthcare for all.
The fund's strategy is to generate real-world data and evidence for adoption within broader UK and US healthcare environments, with portfolio companies like Apian working with partners like Zipline and Wing to deliver care to patients faster.
The fund has invested in promising MedTech spin-outs from universities like Cambridge, Oxford, Imperial, King's, and Southampton, counting 12 NHS clinical entrepreneurs amongst its company founders.
The transatlantic fund is designed to stimulate UK healthtech innovation, open up international growth pathways, and create stronger connections between UK and US healthcare ecosystems, ultimately advancing global healthcare innovation and delivery.